Aspirin Use and Incident Cardiovascular Disease, Kidney Failure, and Death in Stable Kidney Transplant Recipients: A Post Hoc Analysis of the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial by Dad, Taimur et al.
Aspirin Use and Incident Cardiovascular Disease, Kidney 
Failure, and Death in Stable Kidney Transplant Recipients: A 
Post Hoc Analysis of the Folic Acid for Vascular Outcome 
Reduction in Transplantation (FAVORIT) Trial
Taimur Dad, MD1, Hocine Tighiouart, MS1,2,3, Alin Joseph, MD, MS1, Andrew Bostom, MD4, 
Myra Carpenter, PhD5, Lawrence Hunsicker, MD6, John W. Kusek, PhD7, Marc Pfeffer, MD, 
PhD8, Andrew S. Levey, MD1, and Daniel E. Weiner, MD, MS1
1Tufts Medical Center and Tufts University School of Medicine, Tufts University, Boston, MA
2The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Tufts 
University, Boston, MA
3Tufts Clinical and Translational Science Institute, Tufts University, Boston, MA
4Rhode Island Hospital, Providence, RI
5University of North Carolina, Chapel Hill, NC
6University of Iowa, Iowa City, IA
7National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
8Brigham and Women’s Hospital, Boston, MA
Abstract
Background—Cardiovascular disease (CVD) is the leading cause of death in kidney transplant 
recipients. Whether aspirin may reduce the risk for CVD, death, and kidney failure outcomes is 
uncertain.
Address correspondence to Daniel E. Weiner, MD, MS, 800 Washington St, Box #391, Boston, MA 02111. 
dweiner@tuftsmedicalcenter.org. 
Because 3 authors of this article are editors for AJKD, the peer-review and decision-making processes were handled entirely by an 
Associate Editor (Jane C. Tan, MD, PhD) who served as Acting Editor-in-Chief. Details of the journal’s procedures for potential editor 
conflicts are given in the Information for Authors & Journal Policies.
Financial Disclosure: Dr Kusek is an employee of the US government. The other authors declare that they have no other relevant 
financial interests.
Contributions: Research idea and study design: TD, HT, AJ, AB, LH, JWK, MP, ASL, DEW; data acquisition: AB, MC, LH, JWK; 
data analysis/interpretation: TD, HT, DEW; statistical analysis: HT, DEW; supervision or mentorship: AB, MC, ASL, DEW. Each 
author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work 
by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and 
resolved. TD, DEW, and HT take responsibility that this study has been reported honestly, accurately, and transparently; that no 
important aspects of the study have been omitted; and that any discrepancies from the study as planned and registered have been 
explained.
Peer Review: Evaluated by 2 external peer reviewers, a statistician, and an Acting Editor-in-Chief.
SUPPLEMENTARY MATERIAL
Note: The supplementary material accompanying this article (http://dx.doi.org/10.1053/j.ajkd.2016.01.019) is available at 
www.ajkd.org
HHS Public Access
Author manuscript
Am J Kidney Dis. Author manuscript; available in PMC 2017 August 01.
Published in final edited form as:
Am J Kidney Dis. 2016 August ; 68(2): 277–286. doi:10.1053/j.ajkd.2016.01.019.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Study Design—Post hoc cohort analysis of FAVORIT, a randomized trial examining the effect 
of homocysteine-lowering vitamins on CVD in kidney transplant recipients.
Setting & Participants—Prevalent adult kidney transplant recipients with 
hyperhomocysteinemia and stable kidney function from the United States, Canada, and Brazil 
participating in FAVORIT, with no known history of CVD.
Predictor—Aspirin use, with aspirin users matched to nonusers using a propensity score.
Outcomes—Incident CVD events, kidney failure, all-cause mortality, a composite of CVD 
events or mortality, and a composite of kidney failure or mortality. Cox proportional hazards 
models with a robust variance to account for the correlation in outcomes within matched pairs 
were sequentially adjusted for demographic, clinical, and laboratory characteristics to assess the 
association between aspirin use and events.
Results—981 aspirin users were matched to 981 nonusers. During a 4-year mean follow up, 
there were 225 CVD events, 200 deaths, 126 kidney failure events, 301 composite kidney failure 
or mortality events, and 324 composite CVD or mortality events. Adjusted models showed no 
significant difference associated with aspirin use in risk for CVD events, all-cause mortality, 
kidney failure, composite of kidney failure or mortality, or composite of primary CVD events or 
mortality (HRs of 1.20 [95% CI, 0.92–1.58], 0.92 [95% CI, 0.69–1.23], 1.19 [95% CI, 0.81–1.74], 
1.03 [0.82–1.31], and 1.11 [95% CI, 0.88–1.38], respectively).
Limitations—We did not examine dose or continued use of aspirin after randomization. CVD 
history is dependent on participant report at baseline. Aspirin use was non–randomly assigned.
Conclusions—Aspirin use is not associated with reduced risk for incident CVD, all-cause 
mortality, or kidney failure in stable kidney transplant recipients with no history of CVD.
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Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in individuals 
with chronic kidney disease (CKD).1 Kidney transplantation is the optimal kidney 
replacement therapy for most individuals with kidney failure, and there were more than 
16,000 kidney transplantations in the United States in 2013.2 Among kidney transplant 
recipients with a functioning transplant, CVD remains the leading cause of death.3,4 The role 
of aspirin in the prevention of CVD in transplant recipients remains unclear.5,6
The American Heart Association and American College of Cardiology recommend aspirin 
for secondary prevention of CVD events for all patients unless contraindicated.7 Aspirin is 
also recommended for primary prevention of CVD events in people at high risk for CKD, 
such as those with diabetic elevated CVD risk (10-year risk for events > 10%), and in 
women with end-stage renal disease.5,6 There remains a lack of clinical trial data in the 
dialysis or kidney transplantation populations, and to date, only limited retrospective data 
show an association between low-dose aspirin therapy and improved transplant survival.6,8
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The Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) trial was a 
multicenter, randomized, double-blind, controlled clinical trial designed to assess whether 
vitamin B supplementation, administered to decrease homocysteine levels, reduced the risk 
for arteriosclerotic CVD outcomes in stable kidney transplant recipients.9 This report 
examines whether reported aspirin use in FAVORIT participants without a history of CVD 
was associated with a reduction in CVD events, kidney failure, or all-cause mortality among 
participants in FAVORIT.
METHODS
Study Design
This post hoc analysis uses data from the FAVORIT trial, an international, double-blind, 
randomized, controlled trial that evaluated whether lowering homocysteine levels using 
vitamin B supplementation would reduce arteriosclerotic CVD outcomes in stable prevalent 
kidney transplant recipients. The FAVORIT trial (ClinicalTrials.gov study number 
NCT00064753) was approved by institutional review boards at participating institutions, and 
all participants provided written informed consent. The data coordinating center at the 
University of North Carolina tracked institutional review board approvals for all sites. The 
current research is conducted under a Data Use Agreement between Tufts Medical Center 
and the University of North Carolina. The design of the trial and baseline characteristics of 
study participants were described previously.10,11 Briefly, 4,110 stable kidney transplant 
recipients were randomly assigned from August 2002 through January 2007 to treatment 
with either a multivitamin that included a high dose or a low dose of folic acid, vitamin B6, 
and vitamin B12. Follow up in-clinic visits were scheduled every 6 months and captured 
events of interest through June 24, 2009. There was no difference in the primary outcome 
between the 2 treatment groups,9 facilitating use of FAVORIT trial data for cohort analyses.
Study Population
Men and women aged 35 to 75 years who had a kidney transplant for at least 6 months were 
screened for eligibility at 30 transplantation centers located in the United States, Canada, 
and Brazil. Inclusion criteria were elevated serum homocysteine level (women, >.11 μmol/L; 
men, >12 μmol/L) and stable kidney function (creatinine clearance: women, >25 mL/min; 
men, >30 mL/min). We excluded from this analysis participants who reported at baseline 
either prior CVD or use of oral anticoagulants or antiplatelet agents other than aspirin 
(warfarin, clopidogrel, and ticlopidine). Participants with missing information at baseline for 
CVD status, aspirin use, or use of other anticoagulants were also excluded (Fig 1).
Participant Characteristics
Baseline demographic information, including age, sex, race, and country of origin, were 
obtained from all participants.11 Also obtained at baseline were medication use (including 
aspirin, statin, type of immunosuppression, anticoagulants other than aspirin, and 
antihypertensive medications), smoking status (classified as current, former, or never), 
medical history (CVD, hypertension, and diabetes mellitus), transplantation characteristics 
(living donor kidney and time since transplantation), physical examination findings (body 
mass index and systolic and diastolic blood pressures), and laboratory variables (serum 
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creatinine, homocysteine, serum total cholesterol, high-density lipoprotein and low-density 
lipoprotein cholesterol, triglycerides, and urine albumin and creatinine). Use of aspirin was 
defined by participant self-report as at least once a week for several months prior to 
randomization during the initial evaluation. Baseline CVD was defined as prior myocardial 
infarction, coronary artery revascularization, stroke, carotid artery revascularization, 
abdominal or thoracic aneurysm repair, and/or lower-extremity arterial revascularization 
based on participant self-report and chart review, if available. Serum creatinine was assayed 
in 2011 from frozen sera obtained at the baseline study visit in 4,016 (98%) participants 
using an alkaline picrate kinetic method on an Olympus AU 400e (Olympus America Inc) 
instrument that was calibrated to an isotope-dilution mass spectrometry–traceable standard. 
Glomerular filtration rate (GFR) was estimated with the 2009 CKD-EPI (CKD 
Epidemiology Collaboration) creatinine equation.12 Self-reported race was categorized as 
white, black, or other; individuals who identified as other and the 27 individuals who had 
missing information were classified as white to estimate GFR. Body mass index was 
calculated as weight in kilograms divided by height in meters squared. Blood pressure was 
measured twice in a seated position at rest and values were averaged. Hypertension was 
defined as either systolic blood pressure > 140 mm Hg, diastolic blood pressure > 90 mm 
Hg, or use of antihypertensive medication at study enrollment. Low-density lipoprotein 
cholesterol level was estimated using the Friedewald equation at triglyceride levels < 400 
mg/dL and measured in the 234 participants with triglyceride levels > 400 mg/dL. Diabetes 
was defined by patient medical history or use of insulin or oral hypoglycemic medications. 
Missing noncritical data were imputed using flexible additive imputation models using the 
transcan function in the R package Hmisc13 (Fig 1).
Study Outcomes
The primary outcomes were CVD events (myocardial infarction, coronary artery 
revascularization, CVD death, stroke, carotid arterial revascularization, abdominal or 
thoracic aneurysm repair, and/or lower-extremity arterial revascularization), kidney failure 
(defined as initiation of dialysis therapy or retransplantation), all-cause mortality, a 
composite of CVD events or all-cause death, and a composite of kidney failure or all-cause 
mortality. Specific causes for kidney failure were not ascertained, and the definition of 
initiation of dialysis therapy required a minimum of 3 months of dialysis therapy or death 
after initiation of dialysis therapy. Composite outcomes were examined to account for semi-
competing risks. Myocardial infarction, CVD-related death, resuscitated sudden death, and 
stroke were centrally reviewed and adjudicated by the trial’s Clinical Endpoints Committee, 
whereas coronary revascularization was identified through medical record review and 
participant interview. The Clinical Endpoints Committee also reviewed medical records 
centrally for unstable angina cases and urgent coronary revascularization procedures in order 
to identify myocardial infarctions not identified by the clinical site staff. Except for 
outcomes involving kidney failure, participants were not censored at the time of return to 
dialysis therapy or at retransplantation.
Statistical Analyses
We first used the propensity score method to match participants who reported aspirin use at 
baseline with those who did not, with the propensity score derived using a logistic regression 
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model accounting for all baseline characteristics listed, including country and random 
assignment to the high- or low-dose multivitamin, 21 different medications (including 
antihypertensive drugs, diabetes medications, and immunosuppression), and laboratory 
values, including uric acid, calcium, albumin, bilirubin, glucose, and alkaline phosphatase 
(Table S1, available as online supplementary material).
After 1:1 matching of aspirin users to nonusers using a greedy matching algorithm with a 
caliper of 0.1 standard deviation (SD) of the propensity score logit scale, we used Cox 
proportional hazards models with a robust variance to account for the correlation in 
outcomes within each matched pair. The robust variance provides marginal treatment effect 
in the unadjusted model as opposed to a stratified Cox proportional hazards model, which 
provides conditional treatment effects. We sequentially adjusted for variables listed in 
participant characteristics, as well as randomization allocation and use of angiotensin-
converting enzyme inhibitors or angiotensin receptor blockers, to evaluate the effect of 
aspirin use on study outcomes. In multivariable models, country of residence was defined as 
United States versus non-United States, estimated GFR (eGFR) was analyzed as a 2-slope 
model with a knot at 45 mL/min/1.73 m2, and diastolic blood pressure was analyzed as a 2-
slope model with a knot at 70 mm Hg. Sensitivity analyses used nonimputed data.
In sensitivity analyses, we performed propensity score matching using 0.2 and 0.3 SDs of 
the propensity score logit scale. Widening of these calipers allows more aspirin users to be 
matched, but with a tradeoff of potentially increasing the imbalance in baseline covariates 
between aspirin users and nonusers. As before, analyses of matched data were performed 
using a Cox proportional hazards model with a robust variance. In additional sensitivity 
analyses, we used inverse probability weighting (IPW) analysis to provide an estimate for 
the average treatment effect on those treated with aspirin using stabilized weights. In the 
IPW analysis, Cox proportional hazards models were fitted with the robust variance to 
account for estimation of propensity score weights. In addition to estimated hazard ratios 
(HRs) between aspirin users and nonusers, cumulative probabilities of events by aspirin 
status and year of follow-up using the propensity score–matching method were generated. 
The 95% confidence intervals (CIs) of the cumulative probabilities and differences between 
aspirin users and non–aspirin users were derived using 500 bootstrap resampling. Finally, to 
appreciate the effect of propensity matching and IPW, the association of aspirin with 
outcomes is assessed using traditional Cox models with multivariable adjustment. Given a 
higher risk for CVD among those with diabetes, we tested the interaction between aspirin 
use and diabetes. Regression imputation and propensity score matching were performed 
using the R packages rms14 and MatchIt,15 respectively. All other analyses were performed 
using SAS, version 9.4 (SAS Institute Inc).
RESULTS
Of 4,110 participants randomly assigned, 15 were missing information for baseline CVD 
status, aspirin use, or other anticoagulant use. An additional 820 were excluded because of 
CVD reported at baseline, and 153 as a result of anticoagulant use other than aspirin. Of the 
remaining 3,122 participants, 2,677 had complete data for all variables, with missing data 
imputed for the other 445 participants; most often missing were lipid levels (Fig 1).
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Of these 3,122 participants (Table 1), 1,124 were aspirin users and 1,998 were nonusers at 
baseline; 981 aspirin users were matched to nonusers using a propensity score. In the 
matched cohort overall (Table 2), mean age was 52 years, with 39% women, 42% with 
diabetes, and 93% with a history of hypertension; 72% were enrolled at a US study site. 
Mean eGFR was 50 mL/min/1.73 m2, median albumin-creatinine ratio was 22 mg/g, and 
mean transplant vintage was 5 years. Standardized differences were <10% for all variables, 
with most <5%. One year after randomization, with data for 84% of participants, 87% of 
original aspirin users remained aspirin users and 88% of nonusers remained nonusers. The 
distribution of propensity scores is shown in Fig S1.
During a mean follow-up of 4 years, 225 primary CVD events, 200 deaths, 126 kidney 
failure events, 301 composite kidney failure or all-cause mortality events, and 324 composite 
primary CVD or all-cause mortality events (Fig 2A and B) were identified. Cumulative event 
probabilities by year are shown in Table 3. About one-third of the 200 deaths identified were 
reported to be CVD related. In adjusted models comparing aspirin users with nonusers, there 
was no difference in incident CVD events, all-cause mortality, kidney failure, kidney failure 
or all-cause mortality, or primary CVD event or all-cause mortality (HRs of 1.20 [95% CI, 
0.92–1.58], 0.92 [95% CI, 0.69–1.23], 1.19 [95% CI, 0.81–1.74], 1.03 [0.82–1.31], and 1.11 
[95% CI, 0.88–1.38], respectively; Table 4). Results were similar in unadjusted models and 
models with fewer adjustments (Table 4).
In sensitivity analyses using propensity score matching with a caliper of 0.2 and 0.3 SDs of 
the propensity score logit scale and using a robust variance rather than a stratified Cox 
analysis, results remained similar (Table S2). Results were also consistent when using IPW 
with average treatment effect in the treated group (Table S3). In traditional Cox proportional 
hazard models, aspirin was associated with a borderline significant increased risk for CVD 
events in multivariable-adjusted models, with no significant association noted for kidney, 
mortality, and composite events (Table S3). The interaction between aspirin and diabetes 
was nonsignificant for all outcomes. Sensitivity analyses excluding participants with 
imputed data showed similar results.
DISCUSSION
In our post hoc analysis of the FAVORIT cohort of stable kidney transplant recipients, using 
successful propensity score matching and sequential multivariable adjustment, we found no 
significant difference in primary CVD events, kidney failure, or all-cause mortality between 
aspirin users and nonusers. CVD is the foremost cause of morbidity and mortality in 
individuals with CKD, both before and after transplantation; accordingly, prevention of 
CVD events is critical in this population. Because no randomized clinical trials of aspirin for 
CVD prevention have been performed in kidney transplant recipients, we are forced to rely 
on observational data and extrapolations from the general population to inform management 
decisions.
In the general population, aspirin is used extensively for secondary prevention and is often 
used for primary prevention of CVD events; however, only limited data exist evaluating the 
role of aspirin for CVD prevention in kidney failure populations despite the high risk for 
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CVD events. Given the lack of large prospective studies examining aspirin use in kidney 
transplant recipients, most of the data are derived from observational studies in transplant 
recipients or people with CKD (including those treated with dialysis). Such studies have 
shown a possible reduction in stroke rate but increased risk for myocardial infarction and 
cardiac events associated with aspirin use in hemodialysis patients,16 reductions in levels of 
proinflammatory cytokines associated with aspirin use in pediatric hemodialysis and 
peritoneal dialysis patients,17 and no significant increase in risk for major bleeding 
associated with aspirin use in patients with non–dialysis-dependent CKD, those treated with 
dialysis, and kidney transplant recipients.18 In one recent study, post hoc subgroup analyses 
showed a significant decrease in cardiovascular events in patients with CKD (defined as 
eGFR < 60 mL/min/1.73 m2) and diastolic hypertension (defined as diastolic blood pressure 
of 100–115 mm Hg) after treatment with aspirin.19 In that analysis, there was also a 
nominally increased (but not statistically significant) bleeding risk noted with lower eGFR 
and aspirin use. Importantly, most of these studies rely on multivariable adjustment and 
nonsystematic event ascertainment.
Establishing the benefit of aspirin use for primary prevention remains an important clinical 
and public health question, especially for populations with an overall increased risk for CVD 
such as those with CKD. Unfortunately, data are lacking to guide primary prevention among 
all patients with CKD, including those with functioning kidney transplants. Based on these 
limited data and extrapolations from the general population, the KDIGO (Kidney Disease: 
Improving Global Outcomes) clinical practice guideline suggests aspirin use in all patients 
with atherosclerotic CVD, but not if there are contraindications. This statement was graded 
2D, based on very low-quality evidence and consistent with uncertain actual benefit.20 
Guideline recommendations also note that aspirin use for primary prevention of CVD in 
transplant recipients with diabetes should be according to patient preferences and balance 
the risk for ischemic events to that of bleeding (2D statement). Within this guideline, the 
work group acknowledged the lack of data and recommends a randomized controlled trial in 
kidney transplant recipients.
Strengths of the current study include using data from the FAVORIT cohort, which is an 
ideal kidney transplantation cohort for this analysis given the large size, detailed baseline 
CVD information and demographics, and close follow-up for an average of 4 years with a 
relatively large number of events. Second, we used propensity score matching in order to 
minimize bias due to confounding given the non-randomized nature of aspirin use, 
implementing a tight (0.1 SD) caliper.21 Using such a tight caliper generated 2 groups of 
participants based on aspirin use with minimal standardized differences in baseline 
demographics. Our data were also analyzed using a less tight caliper of 0.2 and 0.3 SDs for 
the propensity score match and using IPW with consistent results. When we performed 
traditional Cox regression, aspirin use was associated with statistically significant increased 
risk for CVD outcomes, suggesting that the propensity score–matching and IPW strategies 
better account for residual indication bias.22
One limitation in the study is the relatively wide CIs around outcomes, adding modest 
uncertainty to results. Importantly though, unadjusted and parsimonious models for CVD 
outcomes and the composite of CVD outcomes and mortality had fairly tight CIs and HRs 
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that were close to 1. Additional limitations of this observational study include unaccounted 
for confounding. Of note, while unaccounted for confounding should be minimized by the 
matching strategy and further reduced with additional analyses that used sequential 
multivariable adjustment, residual bias may remain. Third, data for other transplant-specific 
characteristics, such as cold ischemia time, donor factors, and dialysis vintage prior to 
transplantation, were not collected in FAVORIT. Fourth, we did not examine the dose or 
continued use of aspirin after baseline randomization. However, at 1 year after 
randomization, few participants crossed over. Fifth, we tried to focus only on aspirin use in 
participants without known CVD; however, CVD may have been under-reported or 
undiagnosed at baseline and aspirin use may be a proxy for this, which could explain the 
nonsignificant trend toward higher CVD-related events in aspirin users. Sixth, we assumed 
that all aspirin use was for cardiovascular protection and not for analgesia because transplant 
recipients are instructed strictly to avoid nonsteroidal anti-inflammatory drugs or aspirin at 
typical pain management doses due to nephrotoxicity. Seventh, we do not have data for 
bleeding complications in participants reporting aspirin use or data regarding causes of 
kidney failure or transplant loss. Finally, there were missing data, which were imputed for 
primary analyses. Importantly, results were similar across models using imputed and 
complete case data.
In conclusion, aspirin use at baseline was not associated with reduction of adverse events in 
stable kidney transplant recipients without known CVD at baseline. A randomized clinical 
trial is needed to conclusively determine whether aspirin use in kidney transplant recipients 
reduces the risk for CVD and other adverse outcomes.
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Figure 1. 
Derivation of the study populations from the Folic Acid for Vascular Outcome Reduction in 
Transplantation (FAVORIT) trial cohort. Abbreviation: CVD, cardiovascular disease.
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Figure 2. 
Event rates per 100 person-years (number of events in parenthesis) for the (A) non–
propensity score–matched and (B) propensity score–matched cohorts. Abbreviation: CVD, 
cardiovascular disease.
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Table 1
Baseline Characteristics of the Study Cohort Prior to Propensity Score Matching
Total (N = 3,122) Aspirin (n = 1,124) No Aspirin (n = 1,998) P
Age, y 50.8 ± 9.3 52.9 ± 9.3 49.7 ± 9.1 <0.001
Female sex 1,242 (40) 430 (38) 812 (41)   0.2
Race <0.001
 White 2,333 (75) 892 (79) 1,441 (72)
 Black 576 (18) 172 (15) 404 (20)
 Other 213 (7) 60 (5) 153 (8)
Country <0.001
 United States 2,204 (71) 830 (74) 1,374 (69)
 Canada 405 (13) 101 (9) 304 (15)
 Brazil 513 (16) 193 (17) 320 (16)
High-dose vitamin treatment arm 1,562 (50) 543 (48) 1,019 (51)   0.2
Low-dose vitamin treatment arm 1,560 (50) 581 (52) 979 (49)   0.2
Diabetes 1,101 (35) 523 (47) 578 (29) <0.001
Hypertension 2,845 (91) 1,052 (94) 1,793 (90) <0.001
Smoking   0.2
 Current 351 (11) 117 (10) 234 (12)
 Former 1,142 (37) 434 (39) 708 (35)
 Never 1,629 (52) 573 (51) 1,056 (53)
Living donor 1,352 (43) 481 (43) 871 (44)   0.7
CNI-based regimen 2,769 (89) 1,012 (90) 1,757 (88)   0.08
Sirolimus use 262 (8) 108 (10) 154 (8)   0.07
Statin use 1,546 (50) 623 (55) 923 (46) <0.001
Graft vintage, y 4.1 [1.7–7.5] 3.3 [1.4–6.7] 4.4 [1.9–8.2] <0.001
BMI, kg/m2 29.1 ± 6.4 29.3 ± 6.3 28.9 ± 6.4   0.2
Systolic BP, mm Hg 135.5 ± 19.4 136.0 ± 20.0 135.3 ± 19.0   0.3
Diastolic BP, mm Hg 79.3 ± 11.9 77.8 ± 11.9 80.1 ± 11.8 <0.001
eGFR, mL/min/1.73 m2 49.6 ± 18.0 50.3 ± 18.1 49.2 ± 17.9   0.1
eGFR strata   0.6
 ≥90 mL/min/1.73 m2 97 (3) 35 (3) 62 (3)
 60–<90 mL/min/1.73 m2 661 (21) 250 (22) 411 (21)
 45–<60 mL/min/1.73 m2 967 (31) 354 (31) 613 (31)
 30–<45 mL/min/1.73 m2 1,024 (33) 362 (32) 662 (33)
 <30 mL/min/1.73 m2 373 (12) 123 (11) 250 (13)
ACR, mg/g 24.7 [8.4–95.6] 19.7 [7.8–64.3] 27.7 [8.9–113.8]   0.009
ACR strata
 <10 mg/g 915 (29) 356 (32) 559 (28) <0.001
 10–29 mg/g 804 (26) 319 (28) 485 (24)
 30–299 mg/g 1,017 (33) 338 (30) 679 (34)
 ≥300 mg/g 386 (12) 111 (10) 275 (14)
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Total (N = 3,122) Aspirin (n = 1,124) No Aspirin (n = 1,998) P
Cholesterol <0.001
 Total, mg/dL 186.5 ± 43.1 182.3 ± 42.7 189.0 ± 43.2
 HDL, mg/dL 47.0 ± 14.2 46.5 ± 13.9 47.2 ± 14.4   0.2
 LDL, mg/dL 102.4 ± 33.5 99.6 ± 32.2 104.0 ± 34.0 <0.001
 Triglycerides, mg/dL 163 [111–235] 159 [109–230] 166 [113–236]   0.08
Note: Values for categorical variables are given as number (percentage); values for continuous variables, as mean ± standard deviation or median 
[interquartile range].
Abbreviations: ACR, albumin-creatinine ratio; BMI, body mass index; BP, blood pressure; CNI, calcineurin inhibitor; eGFR, estimated glomerular 
filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
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Table 2
Baseline Characteristics of Propensity Score–Matched Participants
Total (N = 1,962) Aspirin (n = 981) No Aspirin (n = 981) Std Diff, %
Age, y 52.2 ± 9.2 52.2 ± 9.2 52.2 ± 9.4 −0.2
Female sex 769 (39) 384 (39) 385 (39)   0.2
Race
 White 1,505 (77) 757 (77) 748 (76) −2.2
 Black 338 (17) 165 (17) 173 (18)   2.2
 Other 119 (6) 59 (6) 60 (6)   0.4
Country
 United States 1,413 (72) 712 (73) 701 (71) −2.5
 Canada 186 (9) 96 (10) 90 (9) −2.1
 Brazil 363 (19) 173 (18) 190 (19)   4.5
High-dose vitamin treatment arm 950 (48) 480 (49) 470 (48) −2.0
Low-dose vitamin treatment arm 1,012 (52) 501 (51) 511 (52)   2.0
Diabetes 820 (42) 413 (42) 407 (41) −1.2
Hypertension 1,826 (93) 912 (93) 914 (93)   0.8
Smoking
 Current 201 (10) 103 (11) 98 (10) −1.7
 Former 759 (39) 375 (38) 384 (39)   1.9
 Never 1,002 (51) 503 (51) 499 (51) −0.8
Living donor 862 (44) 424 (43) 438 (45)   2.9
CNI-based regimen 1,761 (90) 876 (89) 885 (90)   3.0
Sirolimus use 175 (9) 86 (9) 89 (9)   1.1
Statin use 1,043 (53) 519 (53) 524 (53)   1.0
Transplant vintage, y 3.6 [1.6–6.8] 3.5 [1.5–6.9] 3.8 [1.7–6.6] −1.6
BMI, kg/m2 29.1 ± 6.3 29.1 ± 6.3 29.1 ± 6.2 −1.0
Systolic BP, mm Hg 136.0 ± 19.5 136.2 ± 20.0 135.9 ± 19.1 −1.4
Diastolic BP, mm Hg 78.7 ± 12.0 78.7 ± 11.9 78.7 ± 12.1   0.1
eGFR, mL/min/1.73 m2 50.0 ± 18.0 50.3 ± 18.2 49.8 ± 17.8 −3.0
eGFR strata
 ≤90 mL/min/1.73 m2 69 (4) 33 (3) 36 (4)   1.7
 60–90 mL/min/1.73 m2 411 (21) 219 (22) 192 (20) −6.8
 45–60 mL/min/1.73 m2 632 (32) 305 (31) 327 (33)   4.8
 30–45 mL/min/1.73 m2 631 (32) 315 (32) 316 (32)   0.2
 <30 mL/min/1.73 m2 219 (11) 109 (11) 110 (11)   0.3
ACR, mg/g 22.1 [7.8–78.5] 21.2 [7.9–69.4] 23.5 [7.7–82.7]   6.1
ACR strata
 <10 mg/g 607 (31) 305 (31) 302 (31) −0.7
 10–29 mg/g 513 (26) 268 (27) 245 (25) −5.3
 30–299 mg/g 632 (32) 307 (31) 325 (33)   3.9
 ≥300 mg/g 210 (11) 101 (10) 109 (11)   2.6
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Total (N = 1,962) Aspirin (n = 981) No Aspirin (n = 981) Std Diff, %
Cholesterol
 Total, mg/dL 184.3 ± 41.8 183.9 ± 43.2 184.8 ± 40.3   2.1
 HDL, mg/dL 46.7 ± 14.0 46.9 ± 14.1 46.6 ± 13.9 −2.2
 LDL, mg/dL 101.0 ± 33.1 100.8 ± 32.9 101.2 ± 33.3   1.2
 Triglycerides, mg/dL 163 [109–234] 160 [109–230] 166 [110–235]   2.1
Note: Values for categorical variables are given as number (percentage); values for continuous variables, as mean 6 standard deviation or median 
[interquartile range].
Abbreviations: ACR, albumin-creatinine ratio; BMI, body mass index; BP, blood pressure; CNI, calcineurin inhibitor; eGFR, estimated glomerular 
filtration rate; HDL, high density lipoprotein; LDL, low density lipoprotein; Std Diff, standardized difference.
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Table 3
Kaplan-Meier Cumulative Probabilities by Aspirin Status, Their Differences, and Year of Follow-up
Cumulative Probability (95% CI)
Aspirin No Aspirin Difference (95% CI)
Primary CVD
 Year 1   3.6% (2.6% to 4.9%)   2.6% (1.6% to 3.7%)   1.0% (−0.5% to 2.5%)
 Year 2   5.9% (4.4% to 7.6%)   5.1% (3.7% to 6.5%)   0.8% (−1.1% to 2.8%)
 Year 3   8.7% (6.9% to 10.7%)   8.0% (6.2% to 9.9%)   0.6% (−1.8% to 3.4%)
 Year 4 11.9% (9.8% to 14.3%) 10.9% (8.7% to 13.2%)   1.0% (−1.9% to 4.2%)
 Year 5 15.5% (12.8% to 18.5%) 13.1% (10.5% to 15.9%)   2.3% (−1.3% to 6.2%)
 Year 6 18.1% (14.6% to 22.0%) 14.7% (11.7% to 17.8%)   3.4% (−1.3% to 8.0%)
 Year 7 20.9% (15.8% to 27.3%) 17.4% (12.2% to 23.8%)   3.5% (−5.5% to 12.5%)
All-cause mortality
 Year 1   1.3% (0.7% to 2.2%)   1.9% (1.0% to 2.8%) −0.5% (−1.7% to 0.6%)
 Year 2   3.3% (2.3% to 4.4%)   4.0% (2.8% to 5.2%) − 0.6% (−2.3% to 1.0%)
 Year 3   6.2% (4.8% to 7.9%)   6.3% (4.8% to 7.8%)   0.0% (−2.2% to 2.1%)
 Year 4   7.9% (6.1% to 9.7%) 10.1% (8.0% to 12.2%) −2.2% (−4.9% to 0.4%)
 Year 5 11.1% (8.7% to 13.5%) 12.7% (10.3% to 15.5%) −1.6% (−5.4% to 1.8%)
 Year 6 15.5% (12.2% to 19.2%) 15.8% (12.5% to 19.2%) −0.3% (−5.0% to 4.9%)
 Year 7 17.7% (13.5% to 22.6%) 22.9% (16.2% to 31.1%) −5.2% (−15.4% to 4.1%)
Kidney failure
 Year 1   0.8% (0.3% to 1.5%)   0.6% (0.2% to 1.2%)   0.2% (−0.5% to 0.9%)
 Year 2   1.7% (1.0% to 2.6%)   2.4% (1.4% to 3.4%) −0.7% (−2.0% to 0.7%)
 Year 3   3.9% (2.6% to 5.2%)   4.2% (2.9% to 5.6%) −0.3% (−2.3% to 1.5%)
 Year 4   5.2% (3.6% to 6.7%)   6.2% (4.5% to 8.1%) −1.0% (−3.6% to 1.3%)
 Year 5   7.6% (5.5% to 9.9%)   8.5% (6.3% to 10.8%) −0.9% (−3.9% to 2.0%)
 Year 6 11.5% (8.2% to 14.6%) 10.7% (7.6% to 14.1%)   0.8% (−3.8% to 5.3%)
 Year 7 13.2% (9.4% to 17.0%) 10.7% (7.6% to 14.1%)   2.6% (−2.6% to 7.6%)
Kidney failure/all-cause mortality
 Year 1   2.2% (1.3% to 3.2%)   2.9% (1.9% to 4.0%) −0.7% (−2.2% to 0.7%)
 Year 2   4.9% (3.6% to 6.3%)   6.1% (4.6% to 7.8%) −1.2% (−3.4% to 0.7%)
 Year 3   9.4% (7.6% to 11.3%) 10.0% (8.0% to 11.8%) −0.6% (−3.3% to 2.0%)
 Year 4 12.0% (9.8% to 14.2%) 15.2% (12.7% to 17.8%) −3.2% (−6.8% to 0.0%)
 Year 5 16.9% (14.1% to 19.6%) 18.9% (16.2% to 21.8%) −2.0% (−6.4% to 2.0%)
 Year 6 24.9% (20.4% to 29.1%) 22.4% (18.8% to 26.2%)   2.4% (−3.7% to 8.2%)
 Year 7 27.1% (21.8% to 32.4%) 24.7% (20.3% to 29.7%)   2.4% (−4.9% to 9.9%)
Primary CVD/all-cause mortality
 Year 1   4.5% (3.4% to 5.9%)   3.6% (2.5% to 4.8%)   0.9% (−0.7% to 2.6%)
 Year 2   7.9% (6.2% to 9.7%)   7.2% (5.6% to 8.8%)   0.7% (−1.6% to 3.0%)
 Year 3 12.2% (10.2% to 14.3%) 11.2% (9.2% to 13.2%)   1.0% (−1.8% to 3.9%)
 Year 4 16.0% (13.5% to 18.5%) 15.8% (13.3% to 18.3%)   0.2% (−3.1% to 3.5%)
 Year 5 20.0% (17.2% to 23.1%) 19.6% (16.6% to 22.7%)   0.4% (−3.7% to 4.5%)
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Cumulative Probability (95% CI)
Aspirin No Aspirin Difference (95% CI)
 Year 6 23.5% (19.9% to 27.2%) 22.1% (18.6% to 25.5%)   1.4% (−3.7% to 6.7%)
 Year 7 26.6% (21.3% to 33.3%) 25.4% (19.6% to 31.8%)   1.3% (−8.0% to 10.9%)
Note: Analyses are based on the 1:1 propensity cohort with a 0.1 standard deviation caliper. The 95% CIs of the cumulative probabilities and the 
differences between aspirin users and non–aspirin users were derived using 500 bootstrap resampling.
Abbreviations: CI, confidence interval; CVD, cardiovascular disease.
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